硫酸-DL-苯异丙胺 | 60-13-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 硫酸-DL-苯异丙胺
• 中文别名: 硫酸氨基丙苯；硫酸-1-苯基-2-丙胺；DL-苯异丙胺硫酸盐
• 英文名称: amphetamine sulfate
• 英文别名: (+/-)-amphetamine sulfate；(1-phenylpropan-2-amine)；d,l-amphetamine sulfate；DL-Amphetamine sulfate；amphetamine sulphate；(DL)-amphetamine；1-phenylpropan-2-amine;sulfuric acid
• CAS: 60-13-9
• 化学式: 2C₉H₁₃N*H₂O₄S
• 分子量: 368.497
• InChiKey: SOFQDLYSFOWTJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.92
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  109
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 储存条件：
  库房应保持通风、低温和干燥的环境。

反应信息

• 作为反应物：
  描述：

  硫酸-DL-苯异丙胺 在 sodium acetate 作用下， 以 溶剂黄146 为溶剂， 生成 5-anthracen-9-ylmethylene-3-(1-methyl-2-phenyl-ethyl)-2-thioxo-thiazolidin-4-one
  参考文献：
  名称：

  Synthesis and study of rhodanines with possible psychostimulant action

  摘要：

  DOI：

  10.1007/bf00760605
• 作为产物：
  描述：

  diethyl (1-phenylpropan-2-yl)phosphoramidate 在 硫酸 作用下， 以 水 为溶剂， 以100 %的产率得到硫酸-DL-苯异丙胺
  参考文献：
  名称：

  Non-distillative Process for Manufacturing High Purity Amphetamines

  摘要：

  The invention provides a non-distillative process for manufacturing amphetamine and substituted amphetamines, comprising obtaining a highly pure phosphoramidate compound, converting the highly pure phosphoramidate compound to an amphetamine sulfate compound, concentrating the amphetamine sulfate compound in isopropanol, and then salting out the amphetamine compound directly to obtain an amphetamine salt, the amphetamine salt selected from amphetamine saccharate, amphetamine sulfate, amphetamine aspartate, alkyl-amphetamine saccharate, alkyl-amphetamine sulfate, alkyl-amphetamine aspartate, aryl-amphetamine saccharate, aryl-amphetamine sulfate, aryl-amphetamine aspartate, and mixtures thereof.

  公开号：

  US20240286993A1

文献信息

• Novel Bicyclic Pyridinones
  申请人：Pettersson Martin Youngjin

  公开号：US20120252758A1

  公开（公告）日：2012-10-04

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物及其药用可接受的盐被披露，其中所述化合物具有如本文所定义的Formula I的结构。相应的药物组合物、治疗方法、合成方法和中间体也被披露。
• Narcotic-NSAID ion pairs
  申请人：Sancilio D. Frederick

  公开号：US20050203115A1

  公开（公告）日：2005-09-15

  The present invention provides an ion pair compound of the formula [narcotic] + [A] − , wherein [narcotic] + represents at least one cation of at least one narcotic agent or one or more stereochemical isomers thereof and [A] − represents at least one anion of at least one NSAID or one or more stereochemical isomers thereof. An example of the ion pair compound is propoxyphene diclofenate. The ion pair compounds, or their pharmaceutical compositions, are useful in methods of treating a wide variety of conditions that indicate analgesics, anti-inflammatory agents, or both. Under the conditions prescribed for their use, the ion pair compounds exhibit poor or complete insolubility but excellent chemical stability in low pH environments, such as those found in the stomach. The ion pair compounds readily dissolve and dissociate in higher pH environments such as the small intestine to release the constituent narcotic and NSAID.

  本发明提供了一种公式为[narcotic]+[A]−的离子对化合物，其中[narcotic]+代表至少一个麻醉剂或其一个或多个立体化学异构体的至少一个阳离子，而[A]−代表至少一个非甾体抗炎药（NSAID）或其一个或多个立体化学异构体的至少一个阴离子。离子对化合物的一个例子是丙氧芬双氯芬酸。这些离子对化合物或其药物组合物在治疗表明需要镇痛剂、抗炎剂或两者都需要的方法中是有用的。在规定的使用条件下，离子对化合物在低pH环境中表现出较差或完全不溶性，但在胃中这类环境中却具有极佳的化学稳定性。离子对化合物在较高pH值的环境中，如小肠，能够快速溶解和离解，以释放组成的麻醉剂和非甾体抗炎药。
• [EN] FAAH INHIBITORS<br/>[FR] INHIBITEURS DE FAAH
  申请人：IRONWOOD PHARMACEUTICALS INC

  公开号：WO2012088469A1

  公开（公告）日：2012-06-28

  The present disclosure relates to compounds useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment or prevention of various disorders. Compounds of the invention are described in Table 1.

  本公开涉及作为脂肪酰胺水解酶（FAAH）抑制剂有用的化合物。该公开还提供包括本公开化合物的药学上可接受的组合物，以及使用这些组合物在治疗或预防各种疾病中的方法。发明的化合物在表1中描述。
• AMINO-HETEROCYCLIC COMPOUNDS
  申请人：Claffey Michelle M.

  公开号：US20100190771A1

  公开（公告）日：2010-07-29

  The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

  这项发明提供了式（I）中的PDE9抑制化合物，以及其药学上可接受的盐，其中R1、R2、R3、A和n的定义如本文所述。还提供了含有式I中化合物的药物组合物，并且提供了在治疗神经退行性和认知障碍疾病，如阿尔茨海默病和精神分裂症中的用途。
• D-AMPHETAMINE COMPOUNDS, COMPOSITIONS, AND PROCESSES FOR MAKING AND USING THE SAME
  申请人：KemPharm, Inc.

  公开号：US20200131130A1

  公开（公告）日：2020-04-30

  Disclosed are d-amphetamine compounds and compositions comprising at least one organic acid covalently bound to d-amphetamine, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.

  揭示了d-安非他明化合物和组合物，其中至少有一种有机酸以共价键结合到d-安非他明，其盐，衍生物或其组合物。还公开了制备和使用这些化合物的方法。